Shamburg News · 8-K filed Nov 12, 2026, 4:09 PM EST

Arcadia Biosciences Reports Third-Quarter 2026 Revenues Up 24% Year-over-Year

RKDA · Arcadia Biosciences, Inc.

  • Earnings
  • Materiality: high

Arcadia Biosciences, Inc. reported third-quarter 2026 total revenues of $1,619 thousand, up 24% from the prior-year quarter, driven by summer programs for its Zola brand. The company reported net income attributable to common stockholders of $1.8 million, or $0.29 per share, compared with $856 thousand in the third quarter of 2025, mainly due to a $2.6 million gain on warrant and option liabilities. For the first nine months of 2026 the company reported a net loss attributable to common stockholders of $8.9 million, or $2.39 per share.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458371.

Written from the filing by Shamburg Markets. Figures are as reported by the company.